, Volume 10, Issue 1, pp 35–51

Death to the bad guys: Targeting cancer via Apo2L/TRAIL



All higher organisms consist of an ordered society of individual cells that must communicate to maintain and regulate their functions. This is achieved through a complex but highly regulated network of hormones, chemical mediators, chemokines and other cytokines, acting as ligands for intra or extra-cellular receptors. Ligands and receptors of the tumor necrosis factor (TNF) superfamilies are examples of signal transducers, whose integrated actions influence the development, homeostasis and adaptive responses of many cells and tissue types. Apo2L/TRAIL is one of several members of the tumour necrosis factor superfamily that induce apoptosis through the engagement of death receptors. Apo2L/TRAIL interacts with an unusually complex receptor system, which in humans comprises two death receptors and three decoy receptors. This molecule has received considerable attention recently because of the finding that many cancer cell types are sensitive to Apo2L/TRAIL-induced apoptosis, while most normal cells appear to be resistant to this action of Apo2L/TRAIL. In this review, we specifically emphasise on the actions of Apo2L/TRAIL with respect to its apoptotic signaling pathways and summarise what is known about its physiological role. The potential therapeutic usefulness of Apo2L/TRAIL, especially in combination with chemotherapeutic agents, is also discussed in some detail.


Apo2L apoptosis death receptors TNF superfamily TRAIL 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nawaz S, Lynch MP, Galand P, Gerschenson LE. Hormonal regulation of cell death in rabbit uterine epithelium. Am J Pathol 1987; 127: 51.PubMedGoogle Scholar
  2. 2.
    Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991; 88: 3412–3415.CrossRefPubMedGoogle Scholar
  3. 3.
    Gerschenson LE, Rotello RJ. Apoptosis, cell proliferation are terms of the growth equation, in apoptosis: The molecular basis of cell death. Cold Spring Harbour Laboratory: Cold Spring Harbour, NY, 1991.Google Scholar
  4. 4.
    Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proc Natl Acad Sci USA 1996; 93: 4192–4196.CrossRefPubMedGoogle Scholar
  5. 5.
    Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485–495.CrossRefPubMedGoogle Scholar
  6. 6.
    Casella CR, Finkel TH. Mechanisms of lymphocyte killing by HIV. Curr Opin Hematol 1997; 4: 24–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH. Activation of caspase-8 in the Alzheimer’s disease brain. Neurobiol Dis 2001; 8: 1006–1016.CrossRefPubMedGoogle Scholar
  8. 8.
    Sanchez Mejia RO, Friedlander RM. Caspases in Huntington’s disease. Neuroscientist 2001; 7: 480–489.PubMedGoogle Scholar
  9. 9.
    Hayakawa K, Takemura G, Koda M, et al. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 2002; 105: 3039–3045.CrossRefPubMedGoogle Scholar
  10. 10.
    Singh AB, Kaushal V, Megyesi JK, Shah, SV, Kaushal GP. Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury. Kidney Int 2002; 62: 106–115.CrossRefPubMedGoogle Scholar
  11. 11.
    Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 998; 4: 31–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973–982.CrossRefPubMedGoogle Scholar
  13. 13.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487–501.CrossRefPubMedGoogle Scholar
  14. 14.
    Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF developmental lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710.CrossRefPubMedGoogle Scholar
  15. 15.
    Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol 1998; 10: 423–434.CrossRefPubMedGoogle Scholar
  16. 16.
    Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998; 393: 478–480.CrossRefPubMedGoogle Scholar
  17. 17.
    Krammer PH. CD95’s deadly mission in the immune system. Nature 2000; 407: 789–795.CrossRefPubMedGoogle Scholar
  18. 18.
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597–3602.CrossRefPubMedGoogle Scholar
  19. 19.
    Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 2004; 101: 3438–3443.CrossRefPubMedGoogle Scholar
  20. 20.
    Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther 1995; 1(2): 75–105.PubMedGoogle Scholar
  21. 21.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994; 76: 959–962.CrossRefPubMedGoogle Scholar
  22. 22.
    Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989; 264: 17595–17605.PubMedGoogle Scholar
  23. 23.
    Banner DW, D’Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 1993; 73: 431–445.CrossRefPubMedGoogle Scholar
  24. 24.
    Karpusas M, Hsu YM, Wang JH, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995; 3: 1031–1039.CrossRefPubMedGoogle Scholar
  25. 25.
    Cha SS, Sung BJ, Kim YA, et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 2000; 275: 31171–31177.CrossRefPubMedGoogle Scholar
  26. 26.
    Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563–571.CrossRefPubMedGoogle Scholar
  27. 27.
    Mongkolsapaya JGJ, Chen N, Xu XN, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6: 1048–1053.CrossRefPubMedGoogle Scholar
  28. 28.
    Hymowitz SG, Ultsch MH, Hurst A, et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633–640.CrossRefPubMedGoogle Scholar
  29. 29.
    Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383–385.CrossRefPubMedGoogle Scholar
  30. 30.
    Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998; 23: 74–79.CrossRefPubMedGoogle Scholar
  31. 31.
    Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275(30): 23319–23325.CrossRefPubMedGoogle Scholar
  32. 32.
    Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682.CrossRefPubMedGoogle Scholar
  33. 33.
    Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690.CrossRefPubMedGoogle Scholar
  34. 34.
    Liabakk NB, Sundan A, Torp S, et al. Development, characterization and use of monoclonal antibodies against sTRAIL: Measurement of sTRAIL by ELISA. J Immunol Methods 2002; 259: 119–128.CrossRefPubMedGoogle Scholar
  35. 35.
    Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL. J Biol Chem 2000; 275: 20632–20637.CrossRefPubMedGoogle Scholar
  36. 36.
    Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997a; 276: 111–113.CrossRefGoogle Scholar
  37. 37.
    Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997b; 277: 815–818.CrossRefGoogle Scholar
  38. 38.
    Chaudhary PM, Eby M, Jasmin A, et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997; 7: 821–830.CrossRefPubMedGoogle Scholar
  39. 39.
    MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417–25420.CrossRefGoogle Scholar
  40. 40.
    Walczak H, Degli Esposti MA, Johnson RS, et al. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. Embo J 1997; 16: 5386–5397.CrossRefPubMedGoogle Scholar
  41. 41.
    Screaton GR, Mongkolsapaya J, Xu XN, et al. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693–696.CrossRefPubMedGoogle Scholar
  42. 42.
    Wu GS, Burns TF, McDonald ER, 3rd, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene [letter]. Nat Genet 1997; 17: 141–143.CrossRefPubMedGoogle Scholar
  43. 43.
    Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–821.CrossRefPubMedGoogle Scholar
  44. 44.
    Degli Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820.CrossRefPubMedGoogle Scholar
  45. 45.
    Mongkolsapaya J, Cowper AE, Xu XN, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998; 160: 3–6.PubMedGoogle Scholar
  46. 46.
    Van Noesel MM, van Bezouw S, Voute PA, et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003; 38(3): 226–233.CrossRefPubMedGoogle Scholar
  47. 47.
    Ruiz de Almodovar C, Lopez-Rivas A, Redondo JM, Rodriguez A. Transcription initiation sites and promoter structure of the human TRAIL-R3 gene. FEBS Lett 2002 6; 531(2): 304–308.CrossRefGoogle Scholar
  48. 48.
    Pan G, Ni J, Yu G, et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998; 424: 41–45.CrossRefPubMedGoogle Scholar
  49. 49.
    Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003–1006.CrossRefPubMedGoogle Scholar
  50. 50.
    Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170.CrossRefPubMedGoogle Scholar
  51. 51.
    Bouralexis S, Findlay DM, Atkins GJ, et al. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: Resensitisation with chemotherapy. Br J Cancer 2003; 89(1): 206–214.CrossRefPubMedGoogle Scholar
  52. 52.
    Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–14367.CrossRefPubMedGoogle Scholar
  53. 53.
    Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734–741.PubMedGoogle Scholar
  54. 54.
    Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62(6): 1619–1623.PubMedGoogle Scholar
  55. 55.
    Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63(5): 912–916.PubMedGoogle Scholar
  56. 56.
    Pritzker LB, Scatena M, Giachelli CM. The Role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004; 15(6): 2834–2841.CrossRefPubMedGoogle Scholar
  57. 57.
    Schneider P, Olson D, Tardivel A, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2003; 14; 278(7): 5444–5454.CrossRefGoogle Scholar
  58. 58.
    Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.PubMedCrossRefGoogle Scholar
  59. 59.
    Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo Nat Med 1999; 5: 157–163.CrossRefPubMedGoogle Scholar
  60. 60.
    Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: A novel lethal weapon against malignant glioma? FEBS Lett 998; 427: 124–128.CrossRefPubMedGoogle Scholar
  61. 61.
    Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999; 5: 2605–2612.PubMedGoogle Scholar
  62. 62.
    Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817–1824.CrossRefPubMedGoogle Scholar
  63. 63.
    Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 2000; 60: 2384–2389.PubMedGoogle Scholar
  64. 64.
    Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 2001; 98: 795–804.CrossRefPubMedGoogle Scholar
  65. 65.
    Zhang XD, Franco AV, Nguyen T, et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000b; 164: 3961–3970.Google Scholar
  66. 66.
    Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002; 99: 491–504.CrossRefPubMedGoogle Scholar
  67. 67.
    Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31–38.PubMedGoogle Scholar
  68. 68.
    Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7: 1362–1369.PubMedGoogle Scholar
  69. 69.
    Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 74: 281–286.CrossRefPubMedGoogle Scholar
  70. 70.
    Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609.CrossRefPubMedGoogle Scholar
  71. 71.
    Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12(6): 611–620.CrossRefPubMedGoogle Scholar
  72. 72.
    Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000; 275: 25065–25068.CrossRefPubMedGoogle Scholar
  73. 73.
    Miyazaki T, Reed JCA. GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2001; 2: 493–500.CrossRefPubMedGoogle Scholar
  74. 74.
    Berger T, Kretzler M. TRAIL-induced apoptosis is independent of the mitochondrial apoptosis mediator DAP3. Biochem Biophys Res Commun 2002; 297: 880–884.CrossRefPubMedGoogle Scholar
  75. 75.
    Green DR. Apoptotic pathways: Paper wraps stone blunts scissors. Cell 2000; 102(1): 1–4.CrossRefPubMedGoogle Scholar
  76. 76.
    Bouillet P, Strasser A. Bax and Bak: Back-bone of T cell death. Nat Immunol 2002; 3(10): 893–894.CrossRefPubMedGoogle Scholar
  77. 77.
    Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501.CrossRefPubMedGoogle Scholar
  78. 78.
    Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481–490.CrossRefPubMedGoogle Scholar
  79. 79.
    Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev 1999; 13: 239–252.PubMedCrossRefGoogle Scholar
  80. 80.
    Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42.CrossRefPubMedGoogle Scholar
  81. 81.
    Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43–53.CrossRefPubMedGoogle Scholar
  82. 82.
    Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. Embo J 1998; 17: 1675–1687.CrossRefPubMedGoogle Scholar
  83. 83.
    Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292, 727–730.CrossRefPubMedGoogle Scholar
  84. 84.
    Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett 2000; 471(1): 93–98.CrossRefPubMedGoogle Scholar
  85. 85.
    Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 2000; 60(11): 3051–3057.PubMedGoogle Scholar
  86. 86.
    Wen J, Ramadevi N, Nguyen D, et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96(12): 3900–3906.PubMedGoogle Scholar
  87. 87.
    Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 276: 37879–37886.PubMedGoogle Scholar
  88. 88.
    LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274–281.CrossRefPubMedGoogle Scholar
  89. 89.
    Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16(1): 33–45.CrossRefPubMedGoogle Scholar
  90. 90.
    Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: Synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res 2002; 62(6): 1583–1587.PubMedGoogle Scholar
  91. 91.
    Zhang XD, Zhang XY, Gray CP, et al. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61: 7339–7348.PubMedGoogle Scholar
  92. 92.
    Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 1998; 10(5): 552–558.CrossRefPubMedGoogle Scholar
  93. 93.
    Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388, 190–195.CrossRefPubMedGoogle Scholar
  94. 94.
    Wang J, Lobito AA, Shen F, et al. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur J Immunol 2000; 30(1): 155–163.CrossRefPubMedGoogle Scholar
  95. 95.
    Kim K, Fisher MJ, Xu SQ, el Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335–346.PubMedGoogle Scholar
  96. 96.
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99(11): 4079–4086.CrossRefPubMedGoogle Scholar
  97. 97.
    Petak I, Douglas L, Tillman DM, et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000; 6(10): 4119–4127.PubMedGoogle Scholar
  98. 98.
    Nimmanapalli R, Porosnicu M, Nguyen D, et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001; 7(2): 350–357.PubMedGoogle Scholar
  99. 99.
    Olsson A, Diaz T, Aguilar-Santelises M, et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001; 15: 1868–1877.PubMedGoogle Scholar
  100. 100.
    Atkins GJ, Bouralexis S, Evdokiou A, et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002; 31: 448–456.CrossRefPubMedGoogle Scholar
  101. 101.
    Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interferon Cytokine Res 2001; 21: 313–322.CrossRefPubMedGoogle Scholar
  102. 102.
    Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767–10774.CrossRefPubMedGoogle Scholar
  103. 103.
    Guo BC, Xu YH. Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vitro & in vivo. Acta Pharmacol Sin 2001; 22: 831–836.PubMedGoogle Scholar
  104. 104.
    Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20: 4258–4269.CrossRefPubMedGoogle Scholar
  105. 105.
    Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001; 276: 16484–16490.CrossRefPubMedGoogle Scholar
  106. 106.
    Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem 2003; 278: 44338–44347.CrossRefPubMedGoogle Scholar
  107. 107.
    Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001; 276: 6893–6896.CrossRefPubMedGoogle Scholar
  108. 108.
    Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964–3973.CrossRefPubMedGoogle Scholar
  109. 109.
    Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001; 276: 27322–27328.CrossRefPubMedGoogle Scholar
  110. 110.
    Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277(5327): 818–821.CrossRefPubMedGoogle Scholar
  111. 111.
    Hu WH, Johnson H, Shu HB. Activation of NF-κB by FADD, Casper, and caspase-8. J Biol Chem 2000; 275: 10838–10844.CrossRefPubMedGoogle Scholar
  112. 112.
    Siegmund D, Hausser A, Peters N, Scheurich P, Wajant H. Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-κ B essential modulator (NEMO)/IKKgamma. J Biol Chem 2001; 276: 43708–43712.CrossRefPubMedGoogle Scholar
  113. 113.
    Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC. NF-κB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 2001; 276: 40385–40388.CrossRefPubMedGoogle Scholar
  114. 114.
    Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J. Disruption of NF-κB signaling reveals a novel role for NF-κB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001; 167: 3164–3173.PubMedGoogle Scholar
  115. 115.
    Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–319.CrossRefPubMedGoogle Scholar
  116. 116.
    Shin EC, Ahn JM, Kim CH, et al. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer 2001; 93: 262–268.CrossRefPubMedGoogle Scholar
  117. 117.
    Lee SH, Shin MS, Kim HS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 2001; 20: 399–403.CrossRefPubMedGoogle Scholar
  118. 118.
    Fisher MJ, Virmani AK, Wu L, et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001; 7: 1688–1697.PubMedGoogle Scholar
  119. 119.
    Bartke T, Siegmund D, Peters N, et al. p53 upregulates cFlip, inhibits transcription of Nf-κB-regulated genes and induces caspase-8-independent cell death in Dld-1 cells. Oncogene 2001; 20: 571–580.CrossRefPubMedGoogle Scholar
  120. 120.
    Meng MER, Sheikh MS, Fornace AJ Jr, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000; 1: 130–144.CrossRefPubMedGoogle Scholar
  121. 121.
    Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735–1743.CrossRefPubMedGoogle Scholar
  122. 122.
    Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and-independent regulation of the death receptor Killer/Dr5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593–1598.PubMedGoogle Scholar
  123. 123.
    Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001; 262: 154–169.CrossRefPubMedGoogle Scholar
  124. 124.
    Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001; 507(3): 381–385.CrossRefPubMedGoogle Scholar
  125. 125.
    Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001; 188, 98–105.CrossRefPubMedGoogle Scholar
  126. 126.
    Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94–100.CrossRefPubMedGoogle Scholar
  127. 127.
    Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356–1361.PubMedGoogle Scholar
  128. 128.
    Sedger LM, Glaccum MB, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32: 2246–2254.CrossRefPubMedGoogle Scholar
  129. 129.
    Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 661–670.PubMedCrossRefGoogle Scholar
  130. 130.
    Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001; 97: 2067–2074.CrossRefPubMedGoogle Scholar
  131. 131.
    Jupp OJ, McFarlane SM, Anderson HM, et al. Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J 2001; 359(Pt 3): 525–535.CrossRefPubMedGoogle Scholar
  132. 132.
    Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2002; 277(1): 575–585.CrossRefPubMedGoogle Scholar
  133. 133.
    Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ, Findlay DM. Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. J Orth Surg 2001; 9: 41–44.Google Scholar
  134. 134.
    Hernandez A, Wang QD, Schwartz SA, Evers BM. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg 2001; 5: 56–65.CrossRefPubMedGoogle Scholar
  135. 135.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 2001; 7: 3874–3883.PubMedGoogle Scholar
  136. 136.
    Vignati S, Codegoni A, Polato F, Broggini M. Trail activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs. Eur J Cancer 2002; 38: 177–183.CrossRefPubMedGoogle Scholar
  137. 137.
    Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164–172.CrossRefPubMedGoogle Scholar
  138. 138.
    Van Valen FFS, Truckenbrod B, Eckervogt V, et al. Apoptotic responsiveness of the Ewing’s sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 2000; 88: 252–259.CrossRefPubMedGoogle Scholar
  139. 139.
    Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283–2294.CrossRefPubMedGoogle Scholar
  140. 140.
    Wu G, Chai J, Suber TL, Wu JW, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008–1012.CrossRefPubMedGoogle Scholar
  141. 141.
    Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001; 165: 263–270.CrossRefPubMedGoogle Scholar
  142. 142.
    Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κ B activity. Leukemia 2001; 15: 921–928.CrossRefPubMedGoogle Scholar
  143. 143.
    Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs 2001b; 10: 1521–1530.CrossRefGoogle Scholar
  144. 144.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800–5806.PubMedGoogle Scholar
  145. 145.
    Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151–153.CrossRefPubMedGoogle Scholar
  146. 146.
    Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365.CrossRefPubMedGoogle Scholar
  147. 147.
    Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255–260.CrossRefPubMedGoogle Scholar
  148. 148.
    Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564–567.CrossRefPubMedGoogle Scholar
  149. 149.
    Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954–960.CrossRefPubMedGoogle Scholar
  150. 150.
    Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553–559.PubMedGoogle Scholar
  151. 151.
    Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ. Role of NF-κB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol 2001; 117: 898–907.CrossRefPubMedGoogle Scholar
  152. 152.
    Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002; 21: 1135–1140.CrossRefPubMedGoogle Scholar
  153. 153.
    Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420–430.CrossRefPubMedGoogle Scholar
  154. 154.
    Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166(8): 4891–4898.PubMedGoogle Scholar
  155. 155.
    Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245(4915): 301–305.CrossRefPubMedGoogle Scholar
  156. 156.
    Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162: 2597–2605.PubMedGoogle Scholar
  157. 157.
    Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163: 920–926.PubMedGoogle Scholar
  158. 158.
    Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451–1460.CrossRefPubMedGoogle Scholar
  159. 159.
    Vidalain PO, Azocar O, Lamouille B, Astier A, Rabourdin-Combe C, Servet-Delprat C. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000; 74: 556–559.PubMedCrossRefGoogle Scholar
  160. 160.
    Phillips TA, Ni J, Pan G, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J Immunol 1999; 162: 6053–6059.PubMedGoogle Scholar
  161. 161.
    Gong B, Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 2000; 278(3): 747–752.CrossRefPubMedGoogle Scholar
  162. 162.
    Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001; 31(11): 3138–3146.CrossRefPubMedGoogle Scholar
  163. 163.
    Johnsen AC, Haux J, Steinkjer B, et al. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 1999; 11(9): 664–672.CrossRefPubMedGoogle Scholar
  164. 164.
    Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98(7): 2183–2192.CrossRefPubMedGoogle Scholar
  165. 165.
    Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002; 168(4): 1831–1839.PubMedGoogle Scholar
  166. 166.
    Monleon I, Martinez-Lorenzo MJ, Monteagudo L, et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001; 167(12): 6736–6744.PubMedGoogle Scholar
  167. 167.
    Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191(7): 1095–1104.CrossRefPubMedGoogle Scholar
  168. 168.
    Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001; 166(2): 1314–1319.PubMedGoogle Scholar
  169. 169.
    Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315–323.CrossRefPubMedGoogle Scholar
  170. 170.
    Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175–179.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Department of Orthopaedics and TraumaAdelaide University, and Hanson InstituteAdelaideAustralia
  2. 2.St Vincent’s Institute of Medical ResearchFitzroyAustralia
  3. 3.Bone Joint and Cancer GroupSt Vincent’s Institute of Medical ResearchMelbourneAustralia

Personalised recommendations